GTBP - Preclinical data finds GT Biopharma therapy shows promise for tumors; shares up 12%

Preclinical data on GT Biopharma's (NASDAQ:GTBP) GTB-5550 found that the candidate induces natural killer cell activation against a broad spectrum of tumors expressing B7-H3. Shares are up more than 12% in premarket trading. The company also found that a dual camelid bispecific killer engager (BiKE) targeting B7-H3 also display broad activity against B7-H3-expressing tumors. A poster on the data will be presented at the European Society for Medical Oncology Congress this week. GT also said that it would advance GTB-3650, a phase 1 candidate for relapsed/refractory acute myelogenous leukemia and high-risk myelodysplastic syndrome next year. Last month, GT's CEO and CFO abruptly left the company.

For further details see:

Preclinical data finds GT Biopharma therapy shows promise for tumors; shares up 12%